With checkpoint inhibitors we aim to reduce the abnormal response of the immune system.

Inhibitors do not directly fight cancer cells, but rather help the immune system to more effectively identify cancer cells in order to fight them in any part of the body.

T cells are a type of immune cell that fights cancer; immune checkpoint inhibitors are found on the surface of the cells, controlling the immune response.

In general, immune checkpoints deactivate T cells until they are needed, thus preventing T cells from harming normal cells.

Inhibitors are drugs that block the checkpoints to prevent T cells from attacking the cancer.

Immune checkpoint inhibitors

The immune checkpoint inhibitors we use are:

  • Ipilimumab (Yervoy)
  • Nivolumab (Opdivo)
  • Pembrolizumab (Keytruda)

Immune checkpoint inhibitors, both in their anti-CTL4 (Ipilimumab) and anti-PD1 (Nivolumab and Pembrolizumab) versions, allow the patient's immune system's executor lymphocytes to act, attacking the tumor cells by inhibiting the immune checkpoints that prevented this lymphocyte action from occurring.

Our protocols use very low doses (between 20 to 40 times lower than the doses used in official oncological protocols) of these drugs on a weekly basis, so that their possible toxicity and side effects are minimal if not non-existent, without reducing their anticancer efficacy.

Request information without obligation

Request information without obligation, we will study your case with our medical team to give you an answer as soon as possible.